U.S. pharma large copyright scrapped two experimental weight loss products previous yr—a after-daily tablet, lotiglipron, resulting from elevated liver enzymes and a two times-daily tablet, danuglipron, because of robust Unwanted side effects—but CEO Albert Bourla has claimed the com